Obsidian Therapeutics, Inc.

OBX

Last

$13.00

Day

+6.2%

—

52w

—

SPY YTD

+13.3%

XLV

+8.1%

Earnings

—

EMA 21

—

EMA 50

—

EMA 200

—

20d high

—

5y high

—

5y range

—

Website · 87 employees · United States

Positions held

Your positions

OBX isn't in your positions.

Add it to see shares, cost, and P&L here.

Score

—

Hold

—

Signal

—

Target

—

Stop

—

Stop distance

—

Target vs last

—

Fundamentals

Market cap	$756.10M	Enterprise value	$1.05B	Trailing P/E	—	Forward P/E	-5.75
PEG	—	Price / book	-0.93	Beta	2.64	Dividend yield	0.00%
Revenue growth	—	Earnings growth	—	Gross margin	0.0%	Operating margin	0.0%
Profit margin	0.0%	ROE	—	ROA	—	Debt / equity	0.10
Current ratio	2.30	Free cash flow	—	Analyst recommendation	strong_buy	Mean target	$39.00
52w high	$49.97	52w low	$12.07

Quarterly

	2026-Q1	2025-Q1
Revenue	$0.0M	$0.0M
Op margin	—	—
Net income	-$19.6M	-$25.0M
Gross margin	—	—
Gross profit	—	—
Operating income	-$20.3M	-$26.6M

Yearly (6y)

	2025	2024
Revenue	$0.0M	$0.0M
Op margin	—	—
Net income	-$101M	-$83.1M
Gross margin	—	—
Gross profit	—	—
Operating income	-$106M	-$91.3M

Headline scan

No flags

• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).

News

2026-08-13 · Obsidian Therapeutics (OBX) Stock Dropped, So What Is Behind The Attention Now?

2026-08-06 · Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls

2026-08-05 · Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls

2026-08-05 · Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma

Price (daily)

Full chart · RSI · MACD · patterns

No price history yet for OBX.

Quarterly · revenue, net income, margins

Revenue Net income Gross margin Op margin